FDA warns Remedy Meds that its telehealth site misleadingly labels pharmacy-made semaglutide and tirzepatide with approved-drug comparisons.
What happened
In August 2025, FDA reviewed Remedy Meds’ website at https://remedymeds.com and found it offered compounded (pharmacy-made) semaglutide and tirzepatide drug products. FDA said the site claimed the compounded semaglutide had the “same active ingredient as Ozempic and Wegovy” and the compounded tirzepatide had the “same active ingredient as Mounjaro and Zepbound,” which falsely implies they are the same as FDA-approved drugs. FDA called these claims false or misleading, making the products misbranded (false or misleading in labeling or promotion) and illegal to introduce into interstate commerce.
What FDA found
FDA says the claim that compounded semaglutide has the “same active ingredient as Ozempic and Wegovy” falsely implies it is the same as an FDA-approved drug.
FDCA section 502(a) [21 U.S.C. § 352(a)]FDA says the claim that compounded tirzepatide has the “same active ingredient as Mounjaro and Zepbound” falsely implies it is the same as an FDA-approved drug.
FDCA section 502(a) [21 U.S.C. § 352(a)]FDA says the site’s promotional claims are false or misleading, so the compounded drugs are misbranded and cannot be shipped across state lines.
FDCA sections 502(a), 502(bb), and 301(a) [21 U.S.C. §§ 352(a), 352(bb), 331(a)]
What FDA wants
Within 15 working days of receiving the letter, Remedy Meds must send a written response to FDA’s Office of Compounding Quality and Compliance describing the specific steps it has taken to correct the violations, prevent recurrence, and include supporting documents. If it believes the products are not in violation, it must include its reasoning and supporting information.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- compounding pharmacies and marketing partners making approved-drug comparisons
- regulatory and legal teams reviewing online drug promotion
This is a summary. Read the original letter on fda.gov.